Biomarkers.

Alzheimers Dement

Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.

Published: December 2024

Background: The APOE ε4 allele (ApoE4) is a known genetic risk factor for developing Alzheimer's disease (AD). Previous work by our group demonstrated that female ApoE4 homozygotes with Lewy body (LB) pathology were significantly more likely to experience psychosis compared to female ApoE4 non-carriers, whereas there was no dose-dependent difference found in males (Valcic et al., 2022). The objective of this study was to examine LB pathology presence and severity in males and females across ApoE4 status, with a particular interest in female ApoE4 homozygotes.

Method: Demographics, APOE genotype, and LB pathology data was collected in individuals with neuropathologically-confirmed AD (n=1,234) from the National Alzheimer's Coordinating Center (NACC). Bayesian Multilevel Regression was used to predict the probability of LB pathology presence in males and females across ApoE4 status (0, 1, 2 ε4 alleles). An Ordinal Regression was used to examine the relationship between LB pathology severity (brainstem-predominant (mild), limbic or amygdala-predominant (moderate), neocortical-predominant (severe)) and ApoE4 status, stratifying by sex.

Result: While males had a higher probability of exhibiting LB pathology compared to females, after stratifying by ApoE4 status, female ApoE4 homozygotes showed the highest probability of LB pathology at a 91.1% Highest Density Interval (91.1%HDI[0.12: 0.95]) across both sexes. Within females, ApoE4 homozygotes showed a significantly higher probability of having moderate to severe LB pathology relative to other groups (p =.02). Within males, there was no significant relationship between ApoE4 status and LB pathology severity.

Conclusion: This study revealed that sex and zygosity modulate the effect of ApoE4 on presence of LB pathology and LB severity in neuropathologically-confirmed AD patients. Specifically, female ApoE4 homozygotes had the highest probability of having LB pathology, as well as greater LB pathology severity. Future work should explore the association between LB pathology severity and psychosis while stratifying for sex and ApoE4 status. Reference: Valcic, M., Khoury, M. A., Kim, J., Fornazzari, L., Churchill, N. W., Ismail, Z., De Luca, V., Tsuang, D., Schweizer, T.A., Munoz, D.G, & Fischer, C. E. (2022). Determining Whether Sex and Zygosity Modulates the Association between APOE4 and Psychosis in a Neuropathologically-Confirmed Alzheimer's Disease Cohort. Brain Sciences, 12(9), 1266.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.088854DOI Listing

Publication Analysis

Top Keywords

apoe4 status
24
female apoe4
20
apoe4 homozygotes
16
pathology severity
16
apoe4
15
pathology
13
females apoe4
12
probability pathology
12
alzheimer's disease
8
pathology presence
8

Similar Publications

Case-only designs in longitudinal cohorts are a valuable resource for identifying disease-relevant genes, pathways, and novel targets influencing disease progression. This is particularly relevant in Alzheimer's disease (AD), where longitudinal cohorts measure disease "progression," defined by rate of cognitive decline. Few of the identified drug targets for AD have been clinically tractable, and phenotypic heterogeneity is an obstacle to both clinical research and basic science.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Mayo Clinic, Jacksonville, FL, USA.

Background: The immune system is substantially involved in the development and progression of age-related cognitive decline and Alzheimer's disease (AD).

Method: As genetic and environmental factors interactively impact these conditions, we investigated how risk factors such as APOE genotype, age, and sex influence immune activation markers and AD biomarkers in cerebrospinal fluid (CSF) in elderly individuals enrolled in the Mayo Clinic Study of Aging cohort. Among cognitively unimpaired individuals aged over 65 at the baseline visit (N=298), we measured 365 CSF immune activation markers using the proximity extension assay.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

National Center for Neurological Disorders, Shanghai, Shanghai, China.

Background: The heart-brain connection has been proposed to correlate cardiac disorders with brain health. However, the associations between subclinical alterations in cardiac structure or function and Alzheimer's disease (AD) pathologies haven't been fully elucidated. This study aimed to delineate the interrelationships between the subclinical alterations in the left heart, cerebrospinal fluid (CSF) AD biomarkers, and cognition.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA.

Background: APOE genotype is the most important genetic risk factor for Alzheimer's disease (AD), but whether it affects the proteins associated with AD risk is unclear. Circulating proteins may reveal biology underlying pathologic processes.

Methods: We evaluated log2 standardized levels of 4979 proteins quantified using modified aptamer technology [SomaScan] in plasma from 2725 participants in the Cardiovascular Health Study who were free of dementia and stroke.

View Article and Find Full Text PDF

Background: Apolipoprotein ε4 allele (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) with females having higher risk than males. Compared with non-carriers, cognitively normal, middle-aged APOE4 carriers have lower cerebral blood flow (CBF) decades before clinical symptoms appear. Early intervention to protect CBF would be critical for APOE4 carriers to mitigate AD progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!